Erum Siddiqui

Erum Siddiqui

Auto-generated profile, based on publicly available information

Erum Siddiqui

Department of Medicine, Jinnah Sindh Medical University

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
MKMuhammad Saad Khan
Muhammad Saad Khan
DCDevya Khaim Chandani
Devya Khaim Chandani
ESErum Siddiqui
Erum Siddiqui
MKMaliha Khalid
Maliha Khalid
AWAminath Waafira
Aminath Waafira
Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disorder characterized by severe hypertriglyceridemia due to impaired lipoprotein lipase (LPL) function. Traditional treatments like dietary fat restriction and conventional lipid-lowering drugs offer limited benefit due to the underlying genetic deficiency. On December 19, 2024, the Food and Drug Administration approved olezarsen (Tryngolza), an antisense oligonucleotide targeting apolipoprotein C-III (apoC-III), for adults with FCS. By inhibiting apoC-III synthesis, olezarsen enhances LPL activity and facilitates triglyceride clearance. Phase 3 trials demonstrated a significant reduction in triglyceride levels and a marked decrease in pancreatitis episodes, establishing its therapeutic efficacy. Olezarsen is administered monthly via subcutaneous injection, with most adverse events being mild and transient, such as injection site reactions and occasional thrombocytopenia. While short-term outcomes are promising, long-term safety, cost-effectiveness, and broader accessibility remain key concerns. Furthermore, the drug exemplifies the integration of computational biology and precision medicine, laying the foundation for AI-driven innovations in managing rare lipid disorders. Overall, olezarsen represents a major advancement in FCS treatment, addressing an urgent unmet clinical need and reshaping the therapeutic landscape of ultra-rare metabolic diseases.

16 December 2025 in Future Oncology
Verified
Journal Article
Closed access
AJAmna Amir Jalal
Amna Amir Jalal
ZAZain Ul Abideen
Zain Ul Abideen
ESErum Siddiqui
Erum Siddiqui
SDShaikh Muhammad Daniyal
Shaikh Muhammad Daniyal
AAArsalan Ahmed
Arsalan Ahmed
MSMuhammad Salih
Muhammad Salih
This systematic review and meta-analysis compared the diagnostic performance and complication profiles of transperineal biopsy (TPBx) versus transrectal biopsy (TRBx) for prostate cancer, incorporating recent randomized and large observational studies. Following PRISMA 2020 guidelines, PubMed, Scopus, Embase, and Cochrane Library were searched till April 2025. Studies directly comparing TPBx and TRBx were included. Risk of bias was assessed using RoB 2.0 for randomized trials and the Newcastle - Ottawa Scale for observational studies. Pooled relative risks (RRs) with 95% confidence intervals (CIs) were calculated using random-effects models. Subgroup analyses and a GRADE assessment were performed to evaluate the certainty of evidence. Twenty-nine studies (n = 90,621) were included. TPBx showed higher PCa detection (RR 1.08; 95% CI 1.01-1.15; p = 0.02) and csPCa detection (RR 1.14; 95% CI 1.05-1.24; p = 0.001), though the certainty of evidence was low to moderate. Heterogeneity was moderate to high. TPBx also showed lower infection-related complications and comparable overall events, though procedure-related pain was slightly higher. TPBx offers improved diagnostic yield and lower infection risk compared with TRBx, with comparable safety. However, given the moderate heterogeneity and limited high-quality RCTs, further confirmatory trials are necessary. https://www.crd.york.ac.uk/PROSPERO identifier is CRD420251035763.

16 March 2026 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Closed access
AJAmna Amir Jalal
Amna Amir Jalal
SHSyed Ibad Hussain
Syed Ibad Hussain
ESErum Siddiqui
Erum Siddiqui
MKMuhammad Saad Khan
Muhammad Saad Khan
MBMuhammad Burhan
Muhammad Burhan
MAMahrukh Amir
Mahrukh Amir
Injectable PCSK9 inhibitors effectively lower LDL-C levels in patients with hypercholesterolemia; however, their high cost and requirement for parenteral administration limit their widespread use. Oral PCSK9 inhibitors have emerged as a convenient alternative. This review and meta-analysis of the literature evaluate the effectiveness and safety of oral PCSK9 inhibitor treatment for adults with hypercholesterolemia. PubMed, Embase, Cochrane CENTRAL, and Scopus were searched through September 2025 for randomized controlled trials comparing oral PCSK9 inhibitors with placebo. The primary outcome was percentage change in LDL-C, with secondary lipid and safety outcomes. We used Cochrane RoB 2.0 tool to assess risk of bias, and pooled estimates were calculated using a random-effects model. Certainty of evidence was evaluated with GRADE. From 1253 records, 3 trials were included. Participants were mostly men, aged 61–65 years, with elevated baseline LDL-C. Oral PCSK9 inhibitors significantly reduced LDL-C and ApoB in a dose-dependent manner and achieved modest reductions in triglycerides (MD –6.56 mg/dL; 95% CI, −12.30 to −0.83) and total cholesterol (MD –25.25 mg/dL; 95% CI, −30.67 to −19.83). Effects on lipoprotein(a) were inconsistent. Adverse events (RR 1.06; 95% CI, 0.91–1.23) and serious adverse events (RR 1.32; 95% CI, 0.41–4.26) were comparable with placebo. According to our review, oral PCSK9 inhibitors are a promising therapeutic option for treating hypercholesterolemia because of their potent lipid-lowering effects and an overall favorable safety profile. However, more trials are needed to confirm their impact on cardiovascular outcomes.

29 December 2024 in Infection Ecology & Epidemiology
Verified
Journal Article
Open access
ESErum Siddiqui
Erum Siddiqui
MKMaliha Khalid
Maliha Khalid
MKMuhammad Saad Khan
Muhammad Saad Khan
AWAminath Waafira
Aminath Waafira

5 June 2025 in Therapeutic Advances in Vaccines and Immunotherapy
Verified
Journal Article
Open access
ESErum Siddiqui
Erum Siddiqui
MKMohammad Saad Khan
Mohammad Saad Khan
MKMaliha Khalid
Maliha Khalid
HCHarshika Khaim Chandani
Harshika Khaim Chandani
UNUmaimah Naeem
Umaimah Naeem
SWSyed Owais Wasti
Syed Owais Wasti
Background: Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is an ancient disease that continues to pose a significant threat to global public health. Although the BCG vaccine, developed in the 1920s, remains the only approved TB vaccine, it has limited efficacy, particularly against pulmonary TB in adults. The ID93/GLA-SE vaccine, a recombinant subunit vaccine, shows promise by triggering immune solid responses and could be a key solution in combating TB, particularly in the face of rising drug-resistant strains and suboptimal current vaccines. It has the potential to address the unmet need for more effective interventions against drug-resistant TB, a growing global health issue that continues to challenge existing treatment options. Objective: To evaluate the immunogenicity and safety of ID93 + GLA-SE in BCG-vaccinated healthy adults. Methods: A comprehensive electronic search on PubMed (Medline), ScienceDirect, EMBASE, Scopus, and Cochrane Central database was conducted from inception till August 2024 for randomized controlled trials (RCTs) with a target population of BCG-vaccinated healthy adults. This review was conducted according to (PRISMA) criteria and registered with PROSPERO (CRD42024601450). This meta-analysis used Review Manager and forest plots for visual display. The outcomes were displayed as risk ratios (RR) with a 95% confidence interval. Results: The ID93 + GLA-SE vaccine showed strong immunogenicity, particularly in high doses, with robust IgG responses sustained up to day 421 in all studies, significantly higher than baseline, and seroconversion rates remained high through day 84. CD4 T-cell responses peaked after the third dose and remained elevated through day 421, whereas CD8 T-cell responses were minimal. Regarding adverse effects, the ID93 + GLA-SE vaccine significantly increases fatigue (RR 3.24, p = 0.005), myalgia (RR 5.82, p < 0.0001), and injection site pain (RR 4.12, p < 0.00001), compared to placebo, with consistent results across both high and low doses. However, there were no significant differences for upper respiratory tract infections, 0.83 (95% CI 0.38–1.84, p = 0.87) or 1.77 (95% CI 0.77–4.10, p = 0.18) headaches. Dose optimization remains crucial due to the higher side effect risks of increased doses. Conclusion: The ID93 + GLA-SE vaccine shows a solid safety profile and enhances immune responses, especially IgG and CD4+ T-cell activity, which is crucial for TB defense. Higher doses improve efficacy but increase side effects, highlighting the need for dose optimization. As a potential alternative to the BCG vaccine, especially in drug-resistant TB regions, further research should refine dosage and assess long-term safety.

21 November 2025 in BMC Neurology
Verified
Journal Article
Open access
PDF file
ANAdil Nawaz
Adil Nawaz
ABArsalan Bakhtiyar
Arsalan Bakhtiyar
MKMuhammad Ibrahim Khan
Muhammad Ibrahim Khan
ESErum Siddiqui
Erum Siddiqui
EKElsa Khan
Elsa Khan
MTMuhammad Taha
Muhammad Taha
This meta-analysis synthesizes evidence from all available randomized trials and observational cohort studies evaluating the efficacy and safety of ocrelizumab compared to placebo or active comparator therapies. Ocrelizumab (OCR), a monoclonal antibody targeting CD20-positive B-cells, is a high-efficacy therapy for multiple sclerosis (MS). While pivotal trials demonstrate its efficacy in reducing relapses, its impact on disability progression and its safety profile in broader, real-world populations require further synthesis. This systematic review and meta-analysis followed PRISMA guidelines and was registered on PROSPERO (CRD420251012243). We searched PubMed, Embase, and Cochrane Central until August, 2025, for randomized controlled trials (RCTs) and observational studies comparing OCR to placebo or active comparators in adults with MS. Primary outcomes were relapse-related measures and confirmed disability progression (CDP); safety outcomes included infections and malignancies. Twenty-five studies (4 RCTs, 21 observational) were included. OCR was associated with a significant 25% reduction in relapse rates compared to placebo (RR 0.75, 95% CI 0.61–0.93, p = 0.01). However, no significant differences were observed for achieving No Evidence of Disease Activity (NEDA) (RR 1.11, p = 0.13) or CDP (RR 0.90, p = 0.49). Safety analyses revealed no increased risk of overall adverse events, serious infections, or malignancies with OCR. Considerable heterogeneity was observed for several outcomes. This study confirms OCR’s significant efficacy in reducing relapse rates and its manageable safety profile in MS. However, its benefits on composite endpoints like NEDA and on halting disability progression remain uncertain and variable, highlighting a need for long-term studies to better define its role in mitigating disease progression.